Alps Advisors Inc Cyma Bay Therapeutics, Inc. Transaction History

Alps Advisors Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $36,791 - $71,281	2,913 Added 4.02%	75,374 $1.78 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $8,503 - $13,796	783 Added 1.09%	72,461 $1.08 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $69,456 - $101,813	9,298 Added 14.91%	71,678 $784,000
Q1 2023 May 10, 2023	BUY	$5.88 - $9.59 $28,659 - $46,741	4,874 Added 8.48%	62,380 $543,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $185,169 - $360,562	57,506 New	57,506 $360,000

Q4 2018 Feb 04, 2019	SELL	$6.54 - $11.74 $683,430 - $1.23 Million	-104,500 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$10.88 - $14.52 $209,037 - $278,972	19,213 Added 22.53%	104,500 $1.16 Million
Q2 2018 Aug 02, 2018	BUY	$10.66 - $14.38 $909,159 - $1.23 Million	85,287 New	85,287 $1.15 Million

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.